
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded capsule containing amantadine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing amantadine are listed in capsule, tablet and solution forms.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Amantadine is an antiviral and antiparkinson medicine taken by mouth that a pharmacy may compound when a prescriber orders it.
Amantadine is an adamantane antiviral that also eases movement symptoms of Parkinson disease. Against influenza A it blocks the viral M2 protein, which the virus needs to release its genetic material into a cell. In Parkinson disease its action is not fully known; it is a weak NMDA receptor antagonist and may raise dopamine activity. Immediate-release tablets, capsules and oral solution are indicated for prevention and treatment of influenza A, parkinsonism, and drug-induced extrapyramidal reactions. Gocovri extended-release capsules are indicated for dyskinesia in Parkinson disease patients on levodopa-based therapy and as add-on to levodopa and carbidopa for "off" episodes. MedlinePlus lists Osmolex ER as a discontinued brand. A prescriber might order amantadine compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Amantadine labels carry no boxed warning. Warnings include suicide attempts and suicidal thoughts, hallucinations and other psychiatric effects, seizures in people with epilepsy, falling asleep during daily activities, dizziness on standing, heart failure, corneal swelling that can blur vision, and intense urges such as gambling. Overdose can be fatal, and the drug builds up when the kidneys work poorly; Gocovri must not be used in end-stage kidney disease. Untreated angle-closure glaucoma is a reason not to use it. Other anticholinergic drugs and stimulants add to side effects, and quinine, quinidine and triamterene with hydrochlorothiazide can raise its levels. Avoid the nasal live flu vaccine near amantadine use. The label notes possible fetal harm in animals; amantadine passes into breast milk and LactMed advises avoiding it while breastfeeding. Do not stop it suddenly, and talk to your prescriber or pharmacist about side effects.
Amantadine interferes with the transmembrane domain of the influenza A M2 protein; it has little or no activity against influenza B, and resistant influenza A variants circulate, and StatPearls notes the CDC has not recommended it for influenza since 2011. In Parkinson disease it is a weak noncompetitive NMDA receptor antagonist with possible direct and indirect dopaminergic effects and anticholinergic-like side effects. It is well absorbed orally; the immediate-release label gives a time to peak of about 3.3 hours and a half-life of about 17 hours (range 10 to 25) in healthy adults, with largely unchanged renal excretion by glomerular filtration and tubular secretion. Gocovri reaches peak about 12 hours after a bedtime dose; protein binding is about 67%. Labeled indications: influenza A prophylaxis and treatment, parkinsonism and drug-induced extrapyramidal reactions (immediate-release, ANDA); dyskinesia and "off" episodes in Parkinson disease (Gocovri, NDA). StatPearls lists Huntington chorea, multiple sclerosis fatigue, restless legs and traumatic brain injury as uses that are not FDA-approved indications. Abrupt withdrawal has caused parkinsonian crisis and neuroleptic malignant syndrome-like reactions. Dosing is per prescriber, with reduction in renal impairment and age 65 and older. Monitor mood, vision, renal function and orthostatic blood pressure; taper to stop.
Swallow each capsule whole with a glass of water, unless your label says otherwise. Do not crush, chew or open the capsule unless your pharmacist tells you it is safe to do so. Take it at the times shown on your prescription label. If you miss a dose or are unsure how to take it, call the pharmacy.
Capsules are nonaqueous, so under USP <795> they usually carry a beyond-use date of up to 180 days when no other stability data apply. Keep the vial tightly closed at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard any capsules left after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth